Lipid-Lowering Agents - Italy

Italy

The Lipid-Lowering Agents market in Italy is projected to reach a revenue of US$138.80m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2028) of -0.65%, leading to a market volume of US$135.20m by 2028.
In terms of global comparison, United States will generate the highest revenue, amounting to US$4,427.00m in 2024.
Italy has seen a significant increase in the demand for lipid-lowering agents, driven by a growing awareness of cardiovascular health among its population.

Key regions: Italy, Japan, France, Brazil, Australia

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Lipid-Lowering Agents in Italy has been on the rise in recent years.

Customer preferences: Customers in Italy prefer lipid-lowering agents that have fewer side effects and are effective in reducing cholesterol levels. They are also increasingly opting for natural and herbal remedies to manage their cholesterol levels.

Trends in the market: The market for lipid-lowering agents in Italy has been growing steadily, driven by an aging population and increasing awareness about the health risks associated with high cholesterol levels. There has been a shift towards combination therapies that offer better efficacy and are more convenient for patients. The market is also witnessing the entry of new players, offering innovative products to cater to the changing needs of customers.

Local special circumstances: Italy has one of the highest rates of cardiovascular disease in Europe, which has led to a greater emphasis on preventive healthcare measures. The country also has a well-established healthcare system, which provides easy access to medication for patients. However, the market is highly regulated, with strict pricing controls and reimbursement policies, which can limit the profitability of pharmaceutical companies.

Underlying macroeconomic factors: The Italian economy has been struggling in recent years, with low growth and high levels of debt. This has led to a focus on cost containment in the healthcare sector, with the government implementing measures to reduce healthcare spending. This has put pressure on pharmaceutical companies to reduce prices and offer cost-effective solutions. Despite these challenges, the market for lipid-lowering agents in Italy is expected to continue to grow, driven by the increasing prevalence of cardiovascular disease and the growing demand for preventive healthcare measures.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.